文献速递冠心病血脂与心血管预防

中国急性冠脉综合征患者超高危新定义下降脂治疗需求扩大

[The expanding needs on lipid-lowering treatment in patients with acute coronary syndrome by applying newly issued definition of extreme high-risk by Chinese Society of Cardiology].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2020-01-01

基于中国心血管疾病医疗质量改善项目,纳入104 516例住院ACS患者,应用CSC超高危新定义评估降脂治疗需求。结果显示75.1%患者符合超高危标准,93.4%入院LDL-C≥1.4 mmol/L,出院他汀以单药中等强度为主,降脂强度不足。

要点

  • 约3/4住院ACS患者符合CSC超高危新定义。
  • 超高危患者中93.4%入院LDL-C≥1.4 mmol/L。
  • 出院他汀治疗以单药中等强度为主,强度不足。

核心结论

  • 约四分之三的ACS住院患者符合CSC超高危新定义,九成超高危患者入院LDL-C未达新目标,临床降脂强度不足。

研究设计与样本

  • 基于CCC项目的前瞻性注册登记研究,连续纳入全国158家三级医院和82家二级医院2014年11月至2019年7月的ACS住院患者104 516例。

主要发现

  • 75.1%(78 527/104 516)的ACS住院患者符合超高危标准,其中21.2%有≥2次严重ASCVD事件,78.8%有1次严重ASCVD事件合并≥2个高风险因素。
  • 超高危患者入院LDL-C为(2.8±1.0)mmol/L,93.4%(73 307/78 527)入院LDL-C≥1.4 mmol/L,距目标值中位距离1.3(0.8,2.0)mmol/L。
  • 若入院LDL-C降低50%,预计55.6%(43 632/78 527)超高危患者可达标。
  • 在29 947例有出院他汀剂量信息的超高危患者中,93.5%接受他汀治疗,其中95.1%为单药治疗,91.1%为中等强度。

关键数值与推荐

  • CSC专家共识超高危标准:≥2次严重ASCVD事件,或1次严重ASCVD事件合并≥2个高风险因素。
  • 超高危患者LDL-C目标值为1.4 mmol/L。

临床怎么用

  • 对ACS住院患者应常规评估是否符合超高危标准,并据此设定LDL-C目标1.4 mmol/L。
  • 当前出院他汀以单药中等强度为主,需加强降脂强度,考虑联合治疗以缩小达标差距。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To assess the expanding needs on lipid-lowering treatment in patients with acute coronary syndrome (ACS) by applying newly issued definition of extreme high-risk, which is proposed by Chinese expert consensus on lipid management of extreme high-risk atherosclerotic cardiovascular disease (ASCVD) patients of Chinese Society of Cardiology (CSC). Methods: Data of this study was derived from the Improving Care for Cardiovascular Disease in China (CCC) project, which was a case-based nationwide registry study and launched as a collaborative initiative by the American Heart Association and the CSC. The project consecutively recruited ACS patients from158 tertiary hospitals and 82 second hospitals across China, and detailed clinical information of patients was collected. This study enrolled ACS inpatients in CCC project from November 2014 to July 2019. The proportion of extreme high-risk patients, their characteristics, mean LDL-C levels at admission, the gap between measured LDL-C level and the new target, and lipid-lowering therapy at discharge were assessed. Results: Among 104 516 ACS inpatients enrolled in this study, 75.1% (78 527/104 516) met the criteria of extreme high-risk and were expected to achieve the new LDL-C goal. Among patients at extreme high-risk, 21.2% (16 651/78 527) had multiple severe ASCVD events and 78.8% (61 876/78 527) had 1 severe ASCVD event and at least two high-risk factors. For the extreme high-risk patients, the mean level of LDL-C at admission was (2.8±1.0) mmol/L, prevalence of LDL-C ≥1.4 mmol/L was 93.4% (73 307/78 527) and the median gap between LDL-C level at admission and the target of 1.4 mmol/L was 1.3 (0.8, 2.0) mmol/L. If LDL-C could be further reduced to 50% of the admission level, we estimated that 55.6% (43 632/78 527) of the extreme high-risk patients would achieve the new LDL-C goal. Among 40 875 patients with information about discharge statin dosage, 93.5% (28 004/29 947) of the extreme high-risk patients were prescribed with statins at discharge, and among them 95.1% (26 632/28 004) received statin monotherapy and 91.1% (25 501/28 004) were at moderate doses of statins. Conclusion: About three fourth of inpatients with ACS were categorized as extreme high-risk based on the new definition of CSC expert consensuses, nine out of ten patients at extreme high-risk didn't achieve the new LDL-C target at admission, and the intensity of lipid-lowering therapy was insufficient in clinical practice. There are substantially expanding needs for implementing more intensive and effective lipid-lowering strategies. 目的: 评价采用中华医学会心血管病学分会(CSC)《超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识》提出的超高危界定标准对住院急性冠状动脉综合征(ACS)患者降脂治疗需求的影响。 方法: 本研究基于CSC和美国心脏病协会(AHA)合作的中国心血管疾病医疗质量改善项目。该项目是一项基于病例的注册登记研究,在全国158家三级医院和82家二级医院连续入选住院ACS患者,系统地收集患者的临床相关信息。本研究纳入该项目2014年11月至2019年7月入选的所有ACS患者,分析超高危ACS患者的比例和特征,入院时低密度脂蛋白胆固醇(LDL-C)平均水平和距离新LDL-C目标值的差距,以及出院时患者接受降脂治疗的强度和联合用药的情况。 结果: 共纳入104 516例ACS住院患者,其中75.1%(78 527/104 516)的患者符合CSC专家共识提出的超高危动脉粥样硬化性心血管病(ASCVD)的标准,需要达到新的LDL-C目标。在超高危患者中,21.2%(16 651/78 527)的患者发生过≥2次严重ASCVD事件,78.8%(61 876/78 527)的患者发生过1次严重ASCVD事件合并≥2个高风险因素。超高危患者入院时LDL-C水平为(2.8±1.0)mmol/L,且93.4%(73 307/78 527)的患者入院时LDL-C水平≥1.4 mmol/L,未达到1.4 mmol/L目标值的患者LDL-C距目标值的中位距离为1.3(0.8,2.0)mmol/L。如果将患者入院时的LDL-C水平降低50%,预计有55.6%(43 632/78 527)的超高危患者LDL-C水平可以达标。在40 875例收集了出院处方中他汀类药物及剂量信息的患者中,93.5%(28 004/29 947)的超高危患者出院时接受他汀类药物治疗,其中95.1%(26 632/28 004)的患者接受他汀单药治疗,91.1%(25 501/28 004)的患者接受中等强度治疗。 结论: 约3/4的住院ACS患者属于超高危患者,9/10的患者入院时LDL-C水平高于新的LDL-C降脂目标,目前临床常规实施的降脂治疗措施和新的降脂治疗需求之间存在明显差距。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zeng YY, Liu J, Liu J, et al. [The expanding needs on lipid-lowering treatment in patients with acute coronary syndrome by applying newly issued definition of extreme high-risk by Chinese Society of Cardiology]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020. PMID: 33355748. doi:10.3760/cma.j.cn112148-20200710-00549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。